SGLT2 inhibitor for atrial fibrillation, high blood pressure, and high blood sugar
Part of Heart & circulation clinical trials.
This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with paroxysmal atrial fibrillation (a type of irregular heartbeat that comes and goes).
- You have high blood pressure and are already taking medication for it.
- You either have diabetes and are taking medication for it, or you have prediabetes (HbA1c between 6.1% and 6.4%) without needing medication yet.
- You do not have heart failure, severe valve problems, or certain types of cardiomyopathy.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
This trial tests if a medicine (SGLT2 inhibitor) given to people with high blood pressure and early signs of heart stress can help prevent heart failure. You may join if your blood pressure is controlled but tests show your heart is beginning to struggle.
This trial tests if the diabetes drug dapagliflozin can lower the chance of atrial fibrillation (an irregular heartbeat) coming back after a procedure called electrical cardioversion, which uses a shock to restore a normal heart rhythm. If you have AF and are scheduled for cardioversion, you may be able to join.
This trial tests if the medicine dapagliflozin (commonly used for diabetes and heart failure) can help prevent atrial fibrillation from coming back after a catheter ablation. By taking this medicine after your first ablation, researchers hope to reduce the chance of the irregular heartbeat returning.
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
This trial tests whether an SGLT2 inhibitor (a type of diabetes drug) can help prevent heart attacks, strokes, and other heart problems in people with high blood pressure. You may be eligible if you are 60 or older, have high blood pressure, and have had a heart or blood vessel event (like a heart attack or stroke) or have certain risk factors (like smoking, high cholesterol, or obesity).
Hear when a new High blood pressure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.